Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Halberd Corp (OP: HALB )

0.0132 -0.0003 (-2.22%)
Streaming Delayed Price Updated: 3:59 PM EDT, Mar 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,408,681
Open 0.0123
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0135
Today's Range 0.0120 - 0.0160
52wk Range 0.0032 - 0.0220
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Halberd Eradicates All Strains of Antibiotic Resistant E. Coli Provided by the CDC at Youngstown State University
Via ACCESSWIRE
Halberd & Centers for Disease Control to Meet Regarding Eradication of Antibiotic Resistant Pathogens
Via ACCESSWIRE

Performance

YTD
+140.00%
+140.00%
1 Month
-23.26%
-23.26%
3 Month
+65.00%
+65.00%
6 Month
+20.00%
+20.00%
1 Year
-35.29%
-35.29%

More News

Read More
Halberd Demonstrates Simultaneous Eradication of Multiple Strains of CDC Provided Antibiotic Resistant Bacteria
Via ACCESSWIRE
Halberd Corporation Announces Breakthrough in Candida auris Treatment
Via ACCESSWIRE
Halberd Demonstrates Eradication of CDC Provided Antibiotic Resistant Bacteria
Via ACCESSWIRE
Halberd to Conduct Animal Tests of Nasal Spray that Blocks Negative Effects of Head Trauma
Via ACCESSWIRE
Halberd Agrees to Animal Testing at Mississippi State University
Via ACCESSWIRE
Halberd Corporation 2022 Year End CEO Letter and 2023 Goals
Via ACCESSWIRE
Halberd Receives Several Strains of Antibiotic Resistant Bacteria from CDC to Test Laser Eradication
Via ACCESSWIRE
"The Street Podcast" Features Halberd's "Groundbreaking" Cancer Treatment Approach. Listen Now!
Via ACCESSWIRE
CORRECTION: Halberd Team Produces Peer Reviewed Article on Antibody Against Covid-19 Omicron Variant
Via ACCESSWIRE
Halberd Team Produces Peer Reviewed Article on Antibody Against Covid-19 Omicron Variant
Via ACCESSWIRE
Halberd Corporation Achieves Groundbreaking Pre-Clinical Endpoint by Eradicating Cancer Disease Antigen Linked to Breast Cancer
Via ACCESSWIRE
Halberd Signs Development and Marketing Agreement for Medications & Nutraceuticals
Via ACCESSWIRE
Hartman, CEO, and Dr. Felder, CTO of Halberd Corp Featured on The Street Reports Podcast
Via ACCESSWIRE
Halberd Laser Therapy Eliminates over 90% of Multiple Antibiotic Resistant Bacteria in Minutes
Via ACCESSWIRE
Halberd Progresses from Eliminating Top Brain Disease Antigens from CSF To Eradication of Interleukin-6 From Human Blood Serum
Via ACCESSWIRE
Halberd Enters Strategic Alliance for Longevity, Alzheimer's Disease, and Cancer Early Detection, Prevention and Treatment
Via ACCESSWIRE
Halberd Enters Strategic Alliance for Longevity, Alzheimer's Disease, and Cancer Early Detection, Prevention and Treatment
Via Newsfile
Topics Animal Testing Artificial Intelligence
Exposures Animal Testing Artificial Intelligence
Halberd Demonstrates Precise Control of Key Cancer Related T-Cell Protein
Via ACCESSWIRE
NFL Retired Players Association Endorses Halberd Brain Injury Treatment Technology
Via ACCESSWIRE
Halberd Corporation Discusses OTCQB Uplisting and Growing List of Proprietary Technologies with The Stock Day Podcast
Via Newsfile
Topics Intellectual Property
Exposures Intellectual Property
Halberd Corp. Launches "Halberd Cancer Therapeutics, LTD" Wholly Owned Subsidiary
Via ACCESSWIRE
Halberd Corp. Launches "Halberd Cancer Therapeutics, LTD" Wholly Owned Subsidiary
From Halberd Corporation
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Halberd's Antibody Effective Against all 4 SARS-CoV-2 Mutations, Including Omicron
From Halberd Corporation
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.